Search

Displaying results 2441 - 2450 of 2950 in total
  1. Drug

    Fantofarone

    go.drugbank.com/drugs/DB20875
    Experimental

    Fantofarone is a small molecule drug. Fantofarone has a monoisotopic molecular weight of 550.25 Da.

    Categories: P-glycoprotein inhibitors
  2. Drug

    Oxeclosporin

    go.drugbank.com/drugs/DB21134
    Experimental

    Oxeclosporin is a small molecule drug. The usage of the INN stem '-(clo)sporin' in the name indicates that Oxeclosporin is a cyclosporine derivative. Oxeclosporin has a monoisotopic molecular weight of 1261.86 Da.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Befetupitant

    go.drugbank.com/drugs/DB21149
    Experimental

    The usage of the INN stem '-pitant' in the name indicates that Befetupitant is a neurokinin NK1​ (substance P) receptor antagonist. Befetupitant has a monoisotopic molecular weight of 565.22 Da.

  4. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    Oveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1). … [L64068,L64069] It is the first orexin receptor agonist approved by the FDA and the first medicine to treat NT1 by targeting its underlying cause rather than individual symptoms.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Fosrolapitant

    go.drugbank.com/drugs/DB21723
    Investigational

    The usage of the INN stem '-pitant' in the name indicates that Fosrolapitant is a neurokinin NK1​ (substance P) receptor antagonist. Fosrolapitant has a monoisotopic molecular weight of 654.16 Da.

  6. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    [L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. … [A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  8. Drug

    Interferon alfa-n1

    go.drugbank.com/drugs/DB00011
    ApprovedWithdrawn

    Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produc...

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  9. Drug

    Interferon alfa-n3

    go.drugbank.com/drugs/DB00018
    Approved

    Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  10. Drug

    Antihemophilic factor, human recombinant

    go.drugbank.com/drugs/DB00025
    ApprovedInvestigational

    Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells

    Mixtures: HAEMATE P, HAEMATE P